


Curriculum Vitae

**CV must be written in English*

Personal Information



Title (i.e. Prof., Dr., etc.)	Professor
Name (First / Middle / Last)	Byong Duk Ye
Degree (i.e. MD, MSc, PhD, etc.)	MD, MPH, PhD
Country	Republic of Korea
Affiliation	Department of Gastroenterology and Inflammatory Bowel Disease Center, Asan Medical Center, University of Ulsan College of Medicine

Educational Background

1991–1993: Pre-medical course, College of Natural Science, Seoul National University, Seoul, Korea
1993–1997: College of Medicine, Seoul National University, Seoul, Korea
2002–2005: Graduate School of Public Health (Master degree), Seoul National University, Seoul, Korea
2005–2007: Graduate School of Medicine (PhD degree), Seoul National University, Seoul, Korea

Professional Experience

Sep 2021–Present: Director, Inflammatory Bowel Disease Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
Mar 2007–Present: Professor, Gastroenterology and Inflammatory Bowel Disease Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
Feb 2014–Jan 2016: Visiting Scholar, Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, USA
Jan 2023–Present: Associate editor, Inflammatory Bowel Diseases
Jan 2025–Present: Deputy editor, Journal of Gastroenterology and Hepatology

Professional Organizations

Apr 2025–Present: Secretary General, Korean Association for the Study of Intestinal Diseases (KASID)
May 2025–Present: Member, American Gastroenterological Association (AGA) International Subcommittee
Nov 2023–Nov 2025: Director, Scientific Board, Korean Society of Gastroenterology (KSG)
Apr 2023–Apr 2025: Treasurer, Korean Association for the Study of Intestinal Diseases (KASID)
Apr 2021–Apr 2023: Director, Scientific Committee, Korean Association for the Study of Intestinal Diseases (KASID)
Apr 2019–Apr 2021: Director, International Academic Exchange Committee, Korean Association for the Study of Intestinal Diseases (KASID)

Main Scientific Publications

- Seo J, Kim S, Hong SW, et al. Impact of Stopping Thiopurines Under Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: A Population-Based Study. Clin Gastroenterol Hepatol. 2026 Apr 28:S1542-3565(26)00320-4. doi: 10.1016/j.cgh.2026.04.017 (Corresponding author).
- Lee Y, Kim TY, Kim Y, et al. Granzyme K CD8⁺ T Cells with Tissue-Resident Features Promote Intestinal Inflammation in Patients with Crohn's Disease. Exp Mol Med (in press) (Corresponding author).
- Kim K, Yoon AR, Oh K, et al. Association of early vedolizumab trough levels with clinical, biochemical, endoscopic

- response and drug optimization during maintenance therapy in patients with inflammatory bowel diseases. *Sci Rep* 2026;16(1):9289 (Corresponding author).
4. Lee CK, Moon W, Chun J, et al. One-year Safety and Effectiveness of Ustekinumab in Patients With Crohn's Disease: The K-STAR Study. *Inflamm Bowel Dis* 2025;31:1306–1316 (Corresponding author).
5. Lee HS, Lee Y, Baek J, et al. Nonlesional ileal transcriptome in Crohn's disease reveals alterations in immune response and metabolic pathway. *J Gastroenterol Hepatol* 2025;40:208–217 (Corresponding author).
6. Seo J, Kim S, Hong SW, et al. Continuing or stopping 5-aminosalicylates in patients with inflammatory bowel disease on anti-TNF therapy: A nationwide population-based study. *Aliment Pharmacol Ther* 2024;60:389–400 (Corresponding author).
7. Kim K, Park JJ, Yoon H, et al. Application of clinical decision support tools for predicting outcomes with vedolizumab therapy in patients with inflammatory bowel disease: A KASID multicentre study. *Aliment Pharmacol Ther* 2024;59:1539–1550 (Corresponding author).
8. Lee Y, Baek J, Park S, et al. Characterization of Th17 tissue-resident memory cells in non-inflamed intestinal tissue of Crohn's disease patients. *J Autoimmun* 2024;145:103206 (Corresponding author).
9. Kim K, Park S, Lee Y, et al. Transcriptomic Profiling and Cellular Composition of Creeping Fat in Crohn's disease. *J Crohns Colitis* 2024;18:223–232 (Corresponding author).
10. Seo M, Kim Y, Ye BD, et al. Positron emission tomography imaging of system xc⁻ in immune cells for assessment of disease activity in mice and patients with inflammatory bowel disease. *J Nucl Med* 2022;63:1586–1591 (Co-first author).
11. Jung S, Ye BD, Lee HS, et al. Identification of Three Novel Susceptibility Loci for Inflammatory Bowel Disease in Koreans in an Extended Genome-Wide Association Study. *J Crohns Colitis* 2021;15:1898–1907 (Co-first author).
12. Schreiber S, Ben-Horin S, Jaroslaw Leszczyszyn J, et al. Randomized Controlled Trial: Subcutaneous versus Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease. *Gastroenterology* 2021;160:2340–2353 (Corresponding author).